Human Papillomavirus (HPV) Low Risk by in situ Hybridization, Paraffin
Also known as: HPVLR ISH
Use
This test is used to detect low-risk HPV subtypes (genotypes 6, 11, 40, 42, 43, and 44), which are associated with non-cancerous lesions and low risk of progression to cancer. It is particularly useful for assessing the potential cancer risk when a specific focus is more appropriate for high-risk HPV testing, such as in cases of suspected high-grade lesions.
Special Instructions
Preferred test to determine potential cancer risk is Human Papillomavirus (HPV) High Risk by in situ Hybridization, Paraffin (3002008). Include surgical pathology report. Use provided ARUP supply for transport where recommended.
Limitations
This test has not been cleared or approved by the US Food and Drug Administration; it was developed and its performance characteristics determined by ARUP Laboratories, and should be used in a CLIA certified laboratory for clinical purposes. Results may be affected by the quality of the specimen, fixative used, and probe hybridization conditions.
New York Approved
Methodology
Chromosomal / Cytogenetics (CISH)
Biomarkers
LOINC Codes
- 19772-3
- 31208-2
- 48767-8
- 57723-9
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Transport tissue block or 5 unstained positively charged, 5-micron slides in a tissue transport kit (recommended but not required).
Storage Instructions
Protect paraffin block and/or slides from excessive heat.
Causes for Rejection
Paraffin block with no tumor tissue remaining. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinitely |
| Refrigerated | Indefinitely |
| Frozen | Unacceptable |